Dori Thomas-Karyat
![dori-2 dori-2](https://www.elabnyc.com/wp-content/uploads/2018/03/dori-2.jpg)
Synthis
We are developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.
Synthis
We are developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.